SCHEMBL6229280

SCHEMBL6229280

COc1ccc(-c2cc(N)[nH]n2)c(OC)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPL P05186 1/20 0.62
ALDH1A1 P00352 5/20 0.56
GAA P10253 1/20 0.56
MAPK1 P28482 1/20 0.56
HTT P42858 1/20 0.56
GFER P55789 1/20 0.56
KDM4E B2RXH2 4/20 0.51
CYP1A1 P04798 3/20 0.50
CYP1B1 Q16678 3/20 0.50
HPGD P15428 1/20 0.50
TLR9 Q9NR96 2/20 0.48
TLR7 Q9NYK1 1/20 0.48
CYP3A4 P08684 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2E1 P05181 1/20 0.46
CYP2C8 P10632 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2A6 P11509 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP4B1 P13584 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31324689 0.81 HSD17B10 (0.58) ALPLALDH1A1GAAMAPK1KDM4E
SCHEMBL4859841 0.81 HSD17B10 (0.58) ALPLALDH1A1GAAMAPK1KDM4E
SCHEMBL17380970 0.80 TLR8 (0.44) ALPLALDH1A1GAAMAPK1HTT
SCHEMBL8478264 0.77 LMNA (0.60) ALPLALDH1A1GAAMAPK1HTT
SCHEMBL27778769 0.77 ALPL (0.38) ALPLALDH1A1GAAMAPK1HTT
SCHEMBL167088 0.77 MAPT (0.67) ALPLALDH1A1GAAMAPK1KDM4E
SCHEMBL16841246 0.77 KDM4E (0.58) ALPLALDH1A1GAAMAPK1GFER
SCHEMBL13539286 0.77 ALPL (1.00) ALPLALDH1A1GAAMAPK1HTT
SCHEMBL12306207 0.76 HSP90AA1 (0.59) ALDH1A1GAAMAPK1HTTGFER
SCHEMBL15657901 0.76 ALPL (0.55) ALPLALDH1A1GAAMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113283-A1 Methods of treating conditions associated with an EDG-4 receptor MANIV ENERGY CAPITAL 2005-05-26 US disclosed
EP-1513522-A2 METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTOR SRI INTERNATIONAL (US) 2005-03-16 EP disclosed
WO-2003062392-A2 METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTOR CERETEK LLC (US) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113283-A1 Methods of treating conditions associated with an EDG-4 receptor EDNRA, EDNRB, ESRRG ALPL 4550/4885ALDH1A1 2855/4885GAA 896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.